Neuland Laboratories Limited

NSE NEULANDLAB.NS

Neuland Laboratories Limited Receivables for the year ending March 31, 2024: USD 45.08 M

Neuland Laboratories Limited Receivables is USD 45.08 M for the year ending March 31, 2024, a 0.48% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.
  • Neuland Laboratories Limited Receivables for the year ending March 31, 2023 was USD 44.86 M, a 43.14% change year over year.
  • Neuland Laboratories Limited Receivables for the year ending March 31, 2022 was USD 31.34 M, a 4.00% change year over year.
  • Neuland Laboratories Limited Receivables for the year ending March 31, 2021 was USD 30.14 M, a 18.28% change year over year.
  • Neuland Laboratories Limited Receivables for the year ending March 31, 2020 was USD 25.48 M, a 6.76% change year over year.
Key data
Date Receivables Inventory Goodwill Total Assets
Market news
SV Wall Street
NSE: NEULANDLAB.NS

Neuland Laboratories Limited

CEO Mr. Davuluri Sucheth Rao
IPO Date Oct. 13, 2008
Location India
Headquarters Phoenix IVY Building
Employees 1,643
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Chemicals & Advanced Materials Cleaning Supplies Drugstores & Retail Pharmacies Personal Care Plastics
Description

Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was incorporated in 1984 and is headquartered in Hyderabad, India.

StockViz Staff

February 2, 2025

Any question? Send us an email